risperidone

FDA Drug Profile — RISPERDAL CONSTA, RISPERDAL, risperidone, Risperidone, UZEDY

Drug Details

Generic Name
risperidone
Brand Names
RISPERDAL CONSTA, RISPERDAL, risperidone, Risperidone, UZEDY, RISPERDAL M-TAB
Application Number
NDA021346
Sponsor
Alkermes, Inc.
NDC Codes
50
Dosage Forms
INJECTION, SUSPENSION, KIT, TABLET, TABLET, FILM COATED, SOLUTION, INJECTION, SUSPENSION, EXTENDED RELEASE, POWDER, TABLET, ORALLY DISINTEGRATING
Routes
ORAL, SUBCUTANEOUS, INTRAMUSCULAR
Active Ingredients
RISPERIDONE

Indications and Usage

1 INDICATIONS AND USAGE Risperidone is an atypical antipsychotic indicated for: Treatment of schizophrenia ( 1.1 ) As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder ( 1.2 ) Treatment of irritability associated with autistic disorder ( 1.3 ) 1.1 Schizophrenia Risperidone is indicated for the treatment of schizophrenia. Efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see Clinical Studies ( 14.1 )]. 1.2 Bipolar Mania Monotherapy Risperidone is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see Clinical Studies ( 14.2 )] . Adjunctive Therapy Risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in one short-term trial in adults [see Clinical Studies ( 14.3 )] . 1.3 Irritability Associated with Autistic Disorder Risperidone is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. Efficacy was established in 3 short-term trials in children and adolescents (ages 5 to 17 years) [see Clinical Studies ( 14.4 )].